Biotech startups that raised Series B in California, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Prolific Machines | Emeryville | Series B | $50.0M | 2026-10-14 |
| Multiply Labs | San Francisco | Series B | $75.0M | 2026-10-06 |
| Moonwalk Biosciences | South San Francisco | Series B | $70.0M | 2026-09-08 |
| N-Power Medicine | Redwood City | Series B | $32.0M | 2026-09-01 |
| Aureka Biotechnologies | Laguna Hills | Series B | $100.0M | 2026-08-10 |
| LTZ Therapeutics | San Francisco | Series B | $38.0M | 2026-05-06 |
| Unnatural Products | Santa Cruz | Series B | $45.0M | 2026-03-16 |
| BreezeBio | Brisbane | Series B | $60.0M | 2026-02-25 |
8 rows of the CSV in 5 of its 18 columns.
- The 236 biotech startups in California, United States whose last round is Series B have raised $19.4B in total.
- 31 of them closed their most recent round in the last 12 months, $2.4B combined.
- The largest of those rounds is Mirador Therapeutics' $250.0M Series B, dated January 2026.
- The most recent is Prolific Machines' $50.0M Series B on 14 October 2026.
- ARCH Venture Partners is an investor in 5 of them, more than any other fund.
- Health care is the most common other sector, with 203 companies (86%).
- 18% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 11 to 50 employees (55% of companies with a recorded size).
- 2 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 236| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Prolific Machines | Prolific Machines develops light-controlled gene expression systems for producing therapeutics. | Artificial intelligence | Emeryville | Series B | $50.0M | 2026-10-14 | $147.0M | SOSV, Mayfield Fund, SOSV SF & NY (Fka IndieBio) +2 | 51 to 100 | 2020 |
| Multiply Labs | Multiply Labs builds robotic systems that automate biologics manufacturing. | Artificial intelligence | San Francisco | Series B | $75.0M | 2026-10-06 | $97.7M | Y Combinator, Founders Fund, Garage Capital +2 | 11 to 50 | 2016 |
| Moonwalk Biosciences | Moonwalk Biosciences develops precision epigenetic medications through its genomic medicine platform. | Artificial intelligence | South San Francisco | Series B | $70.0M | 2026-09-08 | $127.0M | Google Ventures, Khosla Ventures, ARCH Venture Partners +2 | 11 to 50 | 2022 |
| N-Power Medicine | N-Power Medicine is a biotechnology company that uses AI to offer clinical research and drug development services. | Artificial intelligence | Redwood City | Series B | $32.0M | 2026-09-01 | $104.0M | Merck Global Health Innovation Fund | 101 to 250 | 2021 |
| Aureka Biotechnologies | Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. | Artificial intelligence | Laguna Hills | Series B | $100.0M | 2026-08-10 | $168.4M | K2VC, NRL Capital | 11 to 50 | 2023 |
| LTZ Therapeutics | LTZ Therapeutics develops novel immunotherapies for cancer and other diseases with unmet clinical needs. | Biotech | San Francisco | Series B | $38.0M | 2026-05-06 | $125.0M | Qiming Venture Partners, Shunwei Capital, K2VC +1 | 11 to 50 | 2022 |
| Unnatural Products | Unnatural Products is a biotech company that develops macrocyclic peptide drug therapies. | Artificial intelligence | Santa Cruz | Series B | $45.0M | 2026-03-16 | $83.0M | Abstract, Better Ventures, Artis Ventures +2 | 11 to 50 | 2017 |
| BreezeBio | BreezeBio is a biotechnology company that develops genetic therapies using non-viral delivery to clinically important tissues. | Artificial intelligence | Brisbane | Series B | $60.0M | 2026-02-25 | $127.7M | Sequoia Capital, National Science Foundation, Qiming Venture Partners +1 | 51 to 100 | 2016 |
| Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| Aeovian Pharmaceuticals | Aeovian Pharmaceuticals develops and commercializes therapeutics for rare and age-related diseases. | Biotech | San Francisco | Series B | $55.0M | 2025-12-16 | $142.0M | Sofinnova Investments, venBio Partners, Apollo Health Ventures | 1 to 10 | 2012 |
| BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | San Diego | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
| Profluent Bio | Profluent Bio designs new proteins and gene-editing tools using AI for medicine, agriculture, and science. | Artificial intelligence | Emeryville | Series B | $106.0M | 2025-11-19 | $150.0M | Insight Partners, Spark Capital, AIX Ventures +1 | 11 to 50 | 2022 |
| Gate Bioscience | Gate Bioscience is a biotechnology company developing small molecule treatments for hard-to-treat diseases. | Biotech | Brisbane | Series B | $65.0M | 2025-11-13 | $125.0M | Andreessen Horowitz, Google Ventures, ARCH Venture Partners +1 | 11 to 50 | 2021 |
| Avenzo Therapeutics | Avenzo Therapeutics develops oncology therapies for treating cancer. | Biotech | San Diego | Series B | $60.0M | 2025-09-04 | $841.9M | New Enterprise Associates, Sands Capital Ventures, Lilly Asia Ventures +2 | 11 to 50 | 2022 |
| Actio Biosciences | Actio Biosciences develops drugs for rare diseases through its research center. | Biotech | San Diego | Series B | $66.0M | 2025-06-18 | $121.0M | Canaan Partners, Euclidean Capital, Deerfield Management +2 | 11 to 50 | 2021 |
| Sirius Therapeutics | Sirius Therapeutics is a biotechnology company developing RNAi therapies for cardiovascular diseases. | Biotech | San Diego | Series B | $50.0M | 2025-05-09 | $110.0M | OrbiMed, Hankang Capital, Creacion Ventures +1 | 11 to 50 | 2021 |
| Gallant | Gallant advances investigational stem cell therapies to extend the healthy years of pets. | Biotech | San Diego | Series B | $18.0M | 2025-03-15 | $44.0M | Alumni Ventures, Bling Capital, Science +2 | 11 to 50 | 2018 |
| PictorLabs | PictorLabs offers virtual staining technology powered by its proprietary artificial intelligence models. | Artificial intelligence | Los Angeles | Series B | $30.0M | 2024-09-18 | $48.8M | Insight Partners, M Ventures | 11 to 50 | 2019 |
| Human Longevity Unicorn | Human Longevity is a genomics-based health intelligence company supporting proactive healthcare. | Biotech | San Diego | Series B | $39.8M | 2024-08-21 | $369.8M | StartUp Health, Amino Capital, Threshold +1 | 51 to 100 | 2013 |
| Santa Ana Bio | Santa Ana Bio develops precision immunology therapies for autoimmune and inflammatory diseases. | Biotech | Alameda | Series B | $125.0M | 2024-06-13 | $176.0M | Andreessen Horowitz, Google Ventures, TPG +2 | 11 to 50 | 2022 |
| AltruBio | AltruBio develops targeted antibody therapeutics for cancer and immune-related inflammatory diseases. | Biotech | Los Altos | Series B | $225.0M | 2024-05-21 | $327.6M | RA Capital Management, Blackstone, Cormorant Asset Management +2 | 11 to 50 | 2000 |
| Elegen | Elegen is a biotechnology company that develops microfluidic technology. | Biotech | Menlo Park | Series B | $35.0M | 2024-05-14 | $37.0M | Andreessen Horowitz, 8VC, AME Cloud Ventures +1 | 11 to 50 | 2017 |
| Capstan Therapeutics | Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. | Biotech | San Diego | Series B | $175.0M | 2024-03-20 | $340.0M | RA Capital Management, OrbiMed, Alexandria Venture Investments +2 | 101 to 250 | 2021 |
| Trace Genomics | Trace Genomics analyzes soil genetics to help farmers improve their agricultural practices and crop yields. | Biotech | Burlingame | Series B | $10.5M | 2024-02-20 | $50.2M | AgFunder, S2G Investments, Refactor +1 | 11 to 50 | 2015 |
| HI-Bio | HI-Bio develops therapies for immune-mediated diseases. | Biotech | South San Francisco | Series B | $95.0M | 2024-01-04 | $215.0M | ARCH Venture Partners, Alpha Wave Global, Viking Global Investors +1 | 101 to 250 | 2021 |
| MBrace Therapeutics | MBrace Therapeutics is a privately held biopharmaceutical company. | Biotech | San Diego | Series B | $85.0M | 2023-11-14 | $110.0M | Venrock, TPG, Alta Partners +2 | 11 to 50 | 2019 |
| Genome Insight | Genome Insight develops a platform for whole genome sequence analysis and interpretation. | Biotech | La Jolla | Series B | $23.0M | 2023-11-01 | DSC Investment, Schmidt, InterVest Co. +1 | 11 to 50 | 2020 | |
| Tentarix Biotherapeutics | Tentarix Biotherapeutics creates protein therapeutics with combined bioactivities using synthetic biology. | Biotech | San Diego | Series B | $35.0M | 2023-09-06 | $93.0M | Versant Ventures, Samsara BioCapital, Amplitude Venture Capital | 11 to 50 | 2020 |
| Metagenomi | Metagenomi uses metagenomics and machine learning to discover genome editing systems for therapeutics. | Artificial intelligence | Emeryville | Series B | $100.0M | 2023-01-05 | $466.7M | RA Capital Management, Bristol-Myers Squibb, Marshall Wace +1 | 101 to 250 | 2018 |
| Valitor | Valitor develops novel methods for modifying therapeutic proteins to control their pharmacological properties. | Biotech | Berkeley | Series B | $28.0M | 2022-10-05 | $39.0M | SkyDeck Berkeley, Berkeley SkyDeck Fund, Morningside +2 | 1 to 10 | 2010 |
Table 1. Biotech startups that raised Series B in California, United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 236.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| 2 | Profluent Bio | Profluent Bio designs new proteins and gene-editing tools using AI for medicine, agriculture, and science. | Artificial intelligence | Emeryville | Series B | $106.0M | 2025-11-19 | $150.0M | Insight Partners, Spark Capital, AIX Ventures +1 | 11 to 50 | 2022 |
| 3 | Aureka Biotechnologies | Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. | Artificial intelligence | Laguna Hills | Series B | $100.0M | 2026-08-10 | $168.4M | K2VC, NRL Capital | 11 to 50 | 2023 |
| 4 | BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | San Diego | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
| 5 | Multiply Labs | Multiply Labs builds robotic systems that automate biologics manufacturing. | Artificial intelligence | San Francisco | Series B | $75.0M | 2026-10-06 | $97.7M | Y Combinator, Founders Fund, Garage Capital +2 | 11 to 50 | 2016 |
| 6 | Moonwalk Biosciences | Moonwalk Biosciences develops precision epigenetic medications through its genomic medicine platform. | Artificial intelligence | South San Francisco | Series B | $70.0M | 2026-09-08 | $127.0M | Google Ventures, Khosla Ventures, ARCH Venture Partners +2 | 11 to 50 | 2022 |
| 7 | BreezeBio | BreezeBio is a biotechnology company that develops genetic therapies using non-viral delivery to clinically important tissues. | Artificial intelligence | Brisbane | Series B | $60.0M | 2026-02-25 | $127.7M | Sequoia Capital, National Science Foundation, Qiming Venture Partners +1 | 51 to 100 | 2016 |
| 8 | Aeovian Pharmaceuticals | Aeovian Pharmaceuticals develops and commercializes therapeutics for rare and age-related diseases. | Biotech | San Francisco | Series B | $55.0M | 2025-12-16 | $142.0M | Sofinnova Investments, venBio Partners, Apollo Health Ventures | 1 to 10 | 2012 |
| 9 | Prolific Machines | Prolific Machines develops light-controlled gene expression systems for producing therapeutics. | Artificial intelligence | Emeryville | Series B | $50.0M | 2026-10-14 | $147.0M | SOSV, Mayfield Fund, SOSV SF & NY (Fka IndieBio) +2 | 51 to 100 | 2020 |
| 10 | Unnatural Products | Unnatural Products is a biotech company that develops macrocyclic peptide drug therapies. | Artificial intelligence | Santa Cruz | Series B | $45.0M | 2026-03-16 | $83.0M | Abstract, Better Ventures, Artis Ventures +2 | 11 to 50 | 2017 |
Table 2. Biotech startups that raised Series B in California, United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 5 | 2% | 2 | Moonwalk Biosciences, Mirador Therapeutics |
| 2 | OrbiMed | Private equity firm | New York, United States | 5 | 2% | 2 | Mirador Therapeutics, BlossomHill Therapeutics |
| 3 | Google Ventures | Corporate venture arm | San Francisco, United States | 4 | 2% | 1 | Moonwalk Biosciences |
| 4 | Versant Ventures | Venture capital firm | Menlo Park, United States | 4 | 2% | ||
| 5 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 4 | 2% | ||
| 6 | Alumni Ventures | Angel group | Manchester, United States | 4 | 2% | ||
| 7 | Samsara BioCapital | Private equity firm | Palo Alto, United States | 4 | 2% | ||
| 8 | RA Capital Management | Startup incubator | Boston, United States | 4 | 2% | ||
| 9 | Alpha Wave Global | Private equity firm | Miami, United States | 3 | 1% | 1 | Moonwalk Biosciences |
| 10 | Digitalis Ventures | Venture capital firm | New York, United States | 3 | 1% | ||
| 11 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 3 | 1% | ||
| 12 | SOSV SF & NY (Fka IndieBio) | Venture capital firm | San Francisco, United States | 2 | 1% | 1 | Prolific Machines |
| 13 | SOSV | Venture capital firm | Princeton, United States | 2 | 1% | 1 | Prolific Machines |
| 14 | Y Combinator | Startup accelerator | Mountain View, United States | 2 | 1% | 1 | Multiply Labs |
| 15 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 2 | 1% | 1 | Moonwalk Biosciences |
Table 3. Biotech startups that raised Series B in California, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 203 | 86% | $17.2B |
| Software | 39 | 17% | $3.1B |
| Artificial intelligence | 23 | 10% | $2.1B |
| Hardware | 8 | 3% | $269.0M |
| Cybersecurity | 3 | 1% | $320.7M |
| Fintech | 2 | 1% | $282.7M |
| Commerce | 1 | 0% | $74.4M |
| Energy | 1 | 0% | $74.4M |
Table 4. Biotech startups that raised Series B in California, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 236 | 100% | $33.5M |
Table 5. Biotech startups that raised Series B in California, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Diego | 53 | 22% |
| San Francisco | 34 | 14% |
| South San Francisco | 15 | 6% |
| Palo Alto | 13 | 6% |
| Menlo Park | 10 | 4% |
| Redwood City | 9 | 4% |
| Irvine | 9 | 4% |
| Emeryville | 7 | 3% |
| San Jose | 6 | 3% |
| Mountain View | 5 | 2% |
| Hayward | 5 | 2% |
| Los Angeles | 5 | 2% |
Table 6. Biotech startups that raised Series B in California, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 3 | 10% | $205.0M |
| September 2026 | 4 | 13% | $132.0M |
| August 2026 | 4 | 13% | $291.0M |
| July 2026 | 2 | 6% | $130.0M |
| June 2026 | 3 | 10% | $388.8M |
| May 2026 | 1 | 3% | $38.0M |
| April 2026 | 3 | 10% | $264.0M |
| March 2026 | 1 | 3% | $45.0M |
| February 2026 | 1 | 3% | $60.0M |
| January 2026 | 4 | 13% | $413.8M |
| December 2025 | 4 | 13% | $284.0M |
| November 2025 | 1 | 3% | $106.0M |
Table 7. Biotech startups that raised Series B in California, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 26 | 11% | $2.0B |
| 2025 | 21 | 9% | $1.4B |
| 2024 | 26 | 11% | $1.7B |
| 2023 | 13 | 6% | $711.2M |
| 2022 | 18 | 8% | $645.4M |
| 2021 | 28 | 12% | $1.7B |
Table 8. Biotech startups that raised Series B in California, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 8 | 3% |
| 2020 to 2022 | 35 | 15% |
| 2015 to 2019 | 76 | 32% |
| 2010 to 2014 | 50 | 21% |
| Before 2010 | 67 | 28% |
Table 9. Biotech startups that raised Series B in California, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 40 | 17% |
| 11 to 50 | 129 | 55% |
| 51 to 100 | 40 | 17% |
| 101 to 250 | 15 | 6% |
| 501 to 1,000 | 4 | 2% |
| 1,001 to 5,000 | 1 | 0% |
| 5,001 to 10,000 | 2 | 1% |
| 10,001 or more | 2 | 1% |
Table 10. Biotech startups that raised Series B in California, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in California, United States. On 16 November 2026 that is 236 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 236 rows: 16 have no round amount, 0 no city and 25 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in California, United States whose last round is Series B are on the list?
- 236, in the file dated 16 November 2026. 31 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 236 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.